CClinicalTrials.gg
CompletedNCT04253717Updated May 9, 2023

Motor Control Exercise Program for Pregnant Women With a History of Lumbopelvic Pain

An interventional study of Motor control exercise program in Lumbopelvic Pain, sponsored by Université du Québec à Trois-Rivières. Completed at 1 site in Canada. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2023-05-09.

Sponsored by Université du Québec à Trois-Rivières · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

This study protocol was designed to establish the feasibility of conducting a motor control exercise program with pregnant women presenting a history of lumbopelvic pain (LBPP) in order to reduce LBPP occurrence or limit its intensity. This randomized controlled trial also aims to preliminary assess the effectiveness of the program. To do so, 40 pregnant women with a history of LBPP will be recruited and randomly allocated to one of 2 groups: control (20 participants) or intervention (20 participants). The control group will receive standard care, including basic information on what to do when suffering from LBPP. The intervention group will participate in a weekly 40-minute group session and two more 40-minute weekly home exercise sessions. The motor control exercise program will be designed to target strengthening of the lumbo-pelvic-hip core muscles in order to improve stabilization and protection of the spine and pelvis. Participants of this group will also receive standard care. Adequate prevention and treatment of LBPP, experienced by women during pregnancy, should help reduce LBPP occurrence or limit its intensity during pregnancy.

02

Conditions studied

  • Lumbopelvic Pain

Keywords

  • Physical activity
  • Non-invasive treatment
03

In context

Lead sponsor

Université du Québec à Trois-Rivières is the lead sponsor of 40 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Being pregnant of one fetus
  • Being ≤ 20 weeks pregnant
  • Presenting a history of lumbopelvic pain

Exclusion criteria

Exclusion Criteria:

  • Inflammatory rheumatic disease
  • Infectious disease
  • Neuromuscular disease
  • Vascular disease
  • Connective tissue disease
  • Severe disabling pain
  • Neurologic signs and symptoms
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Motor control exercise program

    Participants will be physically trained during pregnancy and will receive the standard care including basic information on what to do when suffering from lumbopelvic pain.

    Other: Motor control exercise program

  • No intervention
    Control

    Participants will receive the standard care including basic information on what to do when suffering from lumbopelvic pain.

Interventions

  • OtherMotor control exercise program

    Structure physical training aimed at strengthening muscles of the lumbo-pelvic-hip core complex in order to improve stabilization and alignment of the spine and pelvis.

06

What researchers measure

Primary outcomes

  1. Recruitment rate

    Defined as the ability to recruit 40 eligible women, willing to participate to the study

    Time frame: Baseline (Pre-intervention)

  2. Retention rate

    Defined as the completion of follow-up questionnaire by ≥ 80% of women

    Time frame: Baseline (Post-intervention)

  3. Adherence rate

    Defined as attendance to ≥75% of group sessions and ≥ 75% completion of home sessions

    Time frame: Baseline (Post-intervention)

  4. Safety of the intervention

    Determined based on the number of adverse events and defined as nature of adverse events

    Time frame: 16 weeks follow-up

  5. Safety of the intervention

    Determined based on the number of adverse events and defined as nature of adverse events

    Time frame: Week 16 (Post-intervention)

  6. Acceptability of the intervention

    Determined based on how the intervention is perceived by pregnant women (assessed using a 5-point Likert scale : higher score mean a better outcome)

    Time frame: 16 weeks follow-up

  7. Acceptability of the intervention

    Determined based on how the intervention is perceived by pregnant women (assessed using a 5-point Likert scale : higher score mean a better outcome)

    Time frame: Week 16 (Post-intervention)

Secondary outcomes

  1. Functional disability

    Assessed using the Pelvic Girdle Questionnaire (PGQ) (score range from 0 (minimum) to 75 (maximum) : higher score mean a worst outcome)

    Time frame: Baseline (Pre-intervention) and week 16 (Post-intervention)

  2. Fear avoidance behaviors

    Assessed using the Tampa Scale of Kinesiophobia (TSK) (score range from 17 (minimum) to 68 (maximum) : higher score mean a worst outcome)

    Time frame: Baseline (Pre-intervention) and week 16 (Post-intervention)

  3. Level of anxiety

    Assessed using the State-Trait Anxiety Inventory (STAI) (score range from 20 (minimum) to 80 (maximum) : higher score mean a worst outcome)

    Time frame: Baseline (Pre-intervention) and week 16 (Post-intervention)

  4. Depression

    Assessed using the Beck Depression Inventory (BDI) (score range from 0 (minimum) to 63 (maximum) : higher score mean a worst outcome)

    Time frame: Baseline (Pre-intervention) and week 16 (Post-intervention)

  5. Physical activity levels

    Assessed using the Pregnancy Physical Activity Questionnaire (PPAQ) (weekly energy expenditure (MET-h·week-1), score range from 0 (minimum) to 1631 (maximum) : higher score mean a more active person)

    Time frame: Baseline (Pre-intervention) and week 16 (Post-intervention)

  6. Lumbopelvic pain (incidence and frequency)

    Defined as a weekly self-reported incidence and frequency of lumbopelvic pain (determined based on the number of episode)

    Time frame: Baseline (Pre-intervention)

  7. Lumbopelvic pain (incidence and frequency)

    Defined as a weekly self-reported incidence and frequency of lumbopelvic pain (determined based on the number of episode)

    Time frame: 16 weeks follow-up

  8. Lumbopelvic pain (incidence and frequency)

    Defined as a weekly self-reported incidence and frequency of lumbopelvic pain (determined based on the number of episode)

    Time frame: Week 16 (Post-intervention)

  9. Lumbopelvic pain (intensity)

    Defined as a weekly self-reported intensity of lumbopelvic pain using a 100 millimeters visual analog scale

    Time frame: Baseline (Pre-intervention)

  10. Lumbopelvic pain (intensity)

    Defined as a weekly self-reported intensity of lumbopelvic pain using a 100 millimeters visual analog scale

    Time frame: 16 weeks follow-up

  11. Lumbopelvic pain (intensity)

    Defined as a weekly self-reported intensity of lumbopelvic pain using a 100 millimeters visual analog scale

    Time frame: Week 16 (Post-intervention)

07

Study locations

1 site
  • Université du Québec à Trois-Rivières
    Trois-Rivières, Quebec G8Z 4M3, Canada
08

References and documents

Publications

  • Daneau C, Marchand AA, Bussieres A, O'Shaughnessy J, Ruchat SM, Descarreaux M. Effects of a motor control exercise program on lumbopelvic pain recurrences and intensity in pregnant women with a history of lumbopelvic pain: a study protocol for a randomized controlled feasibility trial. Pilot Feasibility Stud. 2022 Mar 21;8(1):65. doi: 10.1186/s40814-022-01024-0. PubMed 35313988 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04253717
Lead sponsor
Université du Québec à Trois-Rivières
Responsible party
Martin Descarreaux (Principal investigator, Université du Québec à Trois-Rivières) — Principal investigator
First posted
Feb 5, 2020
Start date
Apr 2, 2021
Primary completion
Dec 14, 2022
Completion
Dec 14, 2022
Last update
May 9, 2023

Study contacts

Martin Descarreaux, DC, PhD
study director · Université du Québec à Trois-Rivières

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion